Literature DB >> 12478465

Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe.

M Castedo1, J-L Perfettini, T Roumier, G Kroemer.   

Abstract

The cyclin-dependent kinase 1 (Cdk1), formerly called Cdc2 (or p34(Cdc2)), interacts with cyclin B1 to form an active heterodimer. The activity of Cdk1 is subjected to a complex spatiotemporary regulation, required to guarantee its scheduled contribution to the mitotic prophase and metaphase. Moreover, the activation of Cdk1 may be required for apoptosis induction in some particular pathways of cell killing. This applies to several clinically important settings, for instance to paclitaxel-induced killing of breast cancer cells, in which the ErbB2 receptor kinase can mediate apoptosis inhibition through inactivation of Cdk1. The activation of Cdk1 participates also in HIV-1-induced apoptosis, upstream of the p53-dependent mitochondrial permeabilization step. An unscheduled Cdk1 activation may contribute to neuronal apoptosis occurring in neurodegenerative diseases. Finally, the premature activation of Cdk1 can lead to mitotic catastrophe, for instance after irradiation-induced DNA damage. Thus, a cell type-specific modulation of Cdk1 might be taken advantage of for the therapeutic correction of pathogenic imbalances in apoptosis control.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478465     DOI: 10.1038/sj.cdd.4401130

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  111 in total

1.  p21 protects "Super p53" mice from the radiation-induced gastrointestinal syndrome.

Authors:  Julie M Sullivan; Laura B Jeffords; Chang-Lung Lee; Rafaela Rodrigues; Yan Ma; David G Kirsch
Journal:  Radiat Res       Date:  2011-12-13       Impact factor: 2.841

Review 2.  Virus manipulation of cell cycle.

Authors:  R Nascimento; H Costa; R M E Parkhouse
Journal:  Protoplasma       Date:  2011-10-11       Impact factor: 3.356

3.  Survivin and escaping in therapy-induced cellular senescence.

Authors:  Qin Wang; Peter C Wu; Rachel S Roberson; Belinda V Luk; Iana Ivanova; Elizabeth Chu; Daniel Y Wu
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

4.  Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells.

Authors:  Sonam Sinha; Samriddhi Shukla; Sajid Khan; Trygve O Tollefsbol; Syed M Meeran
Journal:  Mol Cell Endocrinol       Date:  2015-02-25       Impact factor: 4.102

5.  Perturbations of cell cycle control in T cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys.

Authors:  M Paiardini; B Cervasi; B Sumpter; H M McClure; D L Sodora; M Magnani; S I Staprans; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Production of reactive oxygen species in response to replication stress and inappropriate mitosis in fission yeast.

Authors:  Maria A Marchetti; Martin Weinberger; Yota Murakami; William C Burhans; Joel A Huberman
Journal:  J Cell Sci       Date:  2006-01-01       Impact factor: 5.285

Review 7.  YAP/TAZ Signaling and Resistance to Cancer Therapy.

Authors:  Chan D K Nguyen; Chunling Yi
Journal:  Trends Cancer       Date:  2019-03-27

8.  Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.

Authors:  Jui-Ling Hsu; Po-Cheng Chiang; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11       Impact factor: 3.000

9.  AKT/eNOS signaling module functions as a potential feedback loop in the growth hormone signaling pathway.

Authors:  Cong-Jun Li; Theodore H Elsasser; Stanislaw Kahl
Journal:  J Mol Signal       Date:  2009-03-25

10.  A class of DNA-binding peptides from wheat bud causes growth inhibition, G2 cell cycle arrest and apoptosis induction in HeLa cells.

Authors:  Loretta Mancinelli; Paula M De Angelis; Lucia Annulli; Valentina Padovini; Kjell Elgjo; Gian Luigi Gianfranceschi
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.